China Universal Asset Management Company’s Spyre Therapeutics SYRE Stock Holding History

China Universal Asset Management Company’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Sell	13,821 -117	-0.8%	-$8.54K	0.07%	186
2026 Q1	$703K	Buy	13,938 +1,294	+10%	+$48.8K	0.05%	231
2025 Q4	$414K	Buy	12,644 +2,057	+19%	+$53.8K	0.03%	276
2025 Q3	$177K	Sell	10,587 -1,535	-13%	-$25K	0.01%	341
2025 Q2	$181K	Buy	12,122 +35	+0.3%	+$518	0.02%	318
2025 Q1	$195K	Sell	12,087 -353	-3%	-$7.34K	0.02%	314
2024 Q4	$290K	Buy	+12,440	New	+$365K	0.03%	298
2022 Q4	–	Sell	-23	Closed	–	–	462
2022 Q3	$0	Buy	+23	New	+$284	﹤0.01%	461

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

China Universal Asset Management Company's SYRE Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Spyre Therapeutics (SYRE) stake by 0.84% in Q2 2026, selling an estimated $8.54K and leaving 13,821 shares worth $1.23M. The position accounts for 0.07% of the portfolio, ranked #186.

China Universal Asset Management Company first reported a position in SYRE in Q3 2022 and has held it in 8 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

China Universal Asset Management Company held 13,821 shares of Spyre Therapeutics worth $1.23M as of Q2 2026.
China Universal Asset Management Company sold 117 Spyre Therapeutics shares in Q2 2026, an estimated $8.54K.
Spyre Therapeutics made up 0.07% of China Universal Asset Management Company's portfolio in Q2 2026, its #186 holding.
China Universal Asset Management Company first reported a position in Spyre Therapeutics in Q3 2022 and has held it in 8 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.